Your browser doesn't support javascript.
loading
Statin Therapy in HIGH-Risk Individuals with NORMal Coronary Arteries: The HIGH-NORM Study.
Chun, Kyeong-Hyeon; Park, Jung Mi; Lee, Chan Joo; Oh, Jaewon; Park, Sungha; Kang, Seok-Min; Lee, Sang-Hak.
Afiliação
  • Chun KH; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
  • Park JM; Department of Biostatistics and Computing, Yonsei University Graduate School.
  • Lee CJ; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
  • Oh J; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
  • Park S; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
  • Kang SM; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
  • Lee SH; Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine.
J Atheroscler Thromb ; 29(7): 1085-1094, 2022 Jul 01.
Article em En | MEDLINE | ID: mdl-34334544
ABSTRACT

AIMS:

Mismatches between the risk status of a patient and coronary imaging data can lead to conflicting strategies to prevent a cardiovascular event. We evaluated whether statin use was associated with cardiovascular benefit in high-risk individuals whose coronary computed tomography angiography (CCTA) results showed normal coronary arteries.

METHODS:

Among asymptomatic individuals whose CCTA showed normal or near normal coronary arteries, 3,389 persons with high- or very-high-risk status were included in this retrospective study. After 12 propensity score matching, 906 individuals (302 new statin users and 604 controls; mean age 61 years; male 58%) were analysed. The primary outcome variable was major adverse cardiovascular and cerebrovascular events (MACCEs) that consisted of cardiovascular death, nonfatal myocardial infarction, coronary revascularisation, and nonfatal ischemic stroke.

RESULTS:

At a median follow-up of 5.8 years, 20 statin users and 17 controls (7.4 and 5.6 events/1,000 person-year, respectively; hazard ratio [HR) 1.04; p=0.92) experienced MACCE. Kaplan-Meier curves showed similar MACCE rates in both groups (p=0.91). In separate analyses for persons with normal (p=0.29) or near normal coronary arteries (p=0.67), MACCE rates did not differ between the groups. Age (HR 1.04; p=0.044), male sex (HR 3.06, p=0.018), and smoking (HR 2.87, p=0.019) were independently associated with MACCEs. In subgroup analyses, no significant factors affected the relationship between statin use and MACCEs.

CONCLUSIONS:

Statin use was not associated with cardiovascular risk reduction in high-risk persons with normal or near normal coronary arteries. More individualised lipid-lowering therapy may benefit this population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Inibidores de Hidroximetilglutaril-CoA Redutases / Infarto do Miocárdio Idioma: En Ano de publicação: 2022 Tipo de documento: Article